Echosens proudly announces the publication of the “FibroScan-AST (FAST) Score in The Lancet Gastroenterology & Hepatology.
Read More
Echosens aligns with the Fatty Liver Foundation to accelerate screening for undiagnosed NAFLD-NASH patients.
Echosens calls for increased vigilance by healthcare providers to monitor liver health at the point of care, address obesity, diabetes and halt progression of NAFLD.
Echosens will provide a live demonstration of a FibroScan examination, in partnership with Fidelis, at the Department of Veterans Affairs’ (VA) National Veterans Small Business Engagement
FAST is a cost-effective tool to help identify individuals at risk for fibrotic NASH, an asymptomatic progressive liver disease that leads to increased liver-related mortality and morbidity.
Echosens joins the American Liver Foundation in observance of Liver Cancer Awareness Month, urging increased awareness of non-alcoholic fatty liver disease (NAFLD) and its more severe form called non-alcoholic steatohepatitis (NASH
Addressing the risk for cirrhosis, liver failure and liver cancer among America’s veterans
Featuring in-depth discussions with physicians and administrators at some of the nation’s leading Federally Qualified Health Centers.
Global Healthcare Business and Technology Expert Leads Company Growth in Chronic Liver Disease Assessment
VA Broadens Contract with Echosens to Include FibroScan mini+ portable Technology, Expands Access to Screening and Early Detection
